ORKA
Oruka Therapeutics, Inc.
There isn't enough reported data to score ORKA yet.
ORKA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ORKA's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
ORKA PE Valuation
ORKA has no meaningful PE right now: it lost money over the past year.
ORKA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Moderate |
Analysts expect ORKA's losses to grow, with revenue holding steady.
ORKA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.10 | +$1.40 |
| Q2 2026 | -$2.02 | +$2.39 |
| Q1 2026 | -$1.93 | +$4.18 |
| Q4 2025 | -$1.85 | +$5.54 |
| Q3 2025 | -$3.50 | +$2.76 |
| Q2 2025 | -$4.41 | +$1.59 |
| Q1 2025 | -$6.11 | -$1.07 |
| Q4 2024 | -$7.39 | -$2.95 |
ORKA is still losing money, but far less than before: $2.10 per share over the past year, against $49.80 at its worst in late 2019.
ORKA Quarterly Revenue
ORKA's revenue is shrinking: $0 last quarter.
ORKA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$44.4M | -$22.7M |
| Q2 2026 | -$33.1M | -$10M |
| Q1 2026 | -$23.7M | -$2.8M |
| Q4 2025 | -$22.7M | -$3.8M |
| Q2 2025 | -$23.2M | -$20.5M |
| Q1 2025 | -$20.9M | -$19.4M |
| Q4 2022 | -$1.5M | +$3.5M |
| Q3 2022 | -$2.5M | +$2.4M |
ORKA has burned cash in almost every quarter: −$124M over the past year, against −$85M the year before.
ORKA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.4% | +1.6M shares |
| 1 year | +40% | +19.4M shares |
| 3 years | +5548% | +66.6M shares |
| 5 years | +5548% | +66.6M shares |
| Available history | +61499% | +67.7M shares |
ORKA has 68M diluted shares, up 40% from a year ago.
ORKA Net Leverage
ORKA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ORKA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.6 | Neutral |
| Stochastic | 69.0 | Neutral |
ORKA's weekly RSI is 65 (neutral) and its Stochastic is 69 (neutral).
ORKA PE vs Healthcare Sector
ORKA has no meaningful PE right now: it lost money over the past year.
ORKA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $88.5 | 19% above |
| 20 week MA | $92.5 | 14% above |
| 50 week MA | $65.5 | 60% above |
| 100 week MA | $40.4 | 160% above |
| 200 week MA | $33.8 | 211% above |
ORKA is in an uptrend: it's above all five of its weekly moving averages, and 211% above its 200-week average.
ORKA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $68.2 | $51.0 | -25% |
| 2021 | $51.0 | $29.5 | -42% |
| 2022 | $29.5 | $28.2 | -4.5% |
| 2023 | $28.2 | $20.4 | -28% |
| 2024 | $20.4 | $19.0 | -6.8% |
| 2025 | $19.0 | $31.7 | +67% |
| 2026 YTD | $31.7 | $105.0 | +231% |
ORKA is up 231% so far in 2026, after finishing lower in five of the previous six years.